This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aarsland, D. Articles by McKeith, I. G. Search for Related Content PubMed PubMed Citation Articles by Aarsland, D. Articles by McKeith, I. G. Social Bookmarking                   What's this?

Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies

Rogaland Central Hospital, Psychiatric Clinic, P.O. Box 1163, Hillevaag, 4095 Stavanger, Norwaydaa{at}sir.no

Urs P. Mosimann, MD

Newcastle General Hospital, Wolfson Research Centre, Newcastle, UK

Ian G. McKeith, MD, F Med Sci

Newcastle General Hospital, Institiute for the Elderly, Newcastle, UK

This article reviews the cholinergic changes in Parkinson’s disease and dementia (PDD) and dementia with Lewy bodies (DLB), their potential clinical implications, and the available evidence for cholinesterase inhibitors in the treatment of PDD and DLB. Marked neuronal loss of cholinergic nuclei, reduced cholinergic markers in the neocortex, hippocampus, and selected thalamic nuclei, and receptor changes have been reported. One large and 2 small placebo-controlled trials and nearly 20 open-label studies suggest that cholinesterase inhibitors have a positive effect on cognition, psychiatric symptoms, and global function in patients with DLB and PDD. The treatment is well tolerated in most patients without any apparent worsening of extrapyramidal motor features. Given the high risk of severe sensitivity reactions and increased risk of cerebrovascular incidents during treatment with neuroleptics, more clinical trials of cholinesterase inhibitors are encouraged to establish their precise role in DLB and PDD. (J Geriatr Psychiatry Neurol 2004; 17:164-171)

Key Words: cholinesterase inhibitors • dementia with Lewy bodies • Parkinson’s disease • treatment

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. A. H. R. Claassen and R. W. M. M. Jansen Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2006; 61(3): 267 - 271. [Abstract] [Full Text] [PDF]

				I. G. McKeith, D. W. Dickson, J. Lowe, M. Emre, J. T. O'Brien, H. Feldman, J. Cummings, J. E. Duda, C. Lippa, E. K. Perry, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium Neurology, December 27, 2005; 65(12): 1863 - 1872. [Abstract] [Full Text] [PDF]

				D. Weintraub and M. B. Stern Psychiatric Complications in Parkinson Disease Am J Geriatr Psychiatry, October 1, 2005; 13(10): 844 - 851. [Abstract] [Full Text] [PDF]